Clinical and Transcriptomic Response to Secukinumab in Korean Patients with Moderate-to-Severe Hidradenitis Suppurativa
Secukinumab demonstrated substantial clinical efficacy and modulated disease-relevant molecular pathways in Korean patients with moderate-to-severe HS. These findings support its therapeutic potential in Asian populations and provide mechanistic insights into IL-17 blockade in HS.
Authors
- H. D. Kim
- Sujin Moon
- J. Shin
- Hee Jung Lee
- Dong Hyun Kim
- Ji Hwan Moon
- Jihee Kim
- Hyun Ah Kwon
- Jung Eun Kim
Institutions
- Yonsei University (KR)
- Soonchunhyang University (KR)
- Samsung Medical Center (KR)
- CHA University Bundang Medical Center (KR)
- CHA University (KR)
Publication Details
- Journal
- Dermatology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1159/000550262
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00